Oxford BioDynamics Announces Strategic Partnership with Boca Biolistics in Order to Advance EpiSwitchâ„¢ Disease Severity Program for COVID-19

Author's Avatar
Nov 02, 2020
Article's Main Image

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing personalized medicine tests based on 3D genomics, has entered into a strategic partnership with Boca Biolistics, a US-based biorepository, reference lab and Contract Research Organization (CRO).